LCM
BCRX icon

Legato Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Legato Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-87,010
Closed -$828K – 702
2026
Q1 		$828K Buy
87,010
+63,061
+263% +$490K 0.08% 351
2025
Q4 		$187K Buy
23,949
+2,172
+10% +$15.7K 0.02% 717
2025
Q3 		$165K Hold
21,777
– – 0.02% 523
2025
Q2 		$195K Sell
21,777
-345
-2% -$3.21K 0.02% 521
2025
Q1 		$166K Sell
22,122
-1,471
-6% -$11.9K 0.02% 522
2024
Q4 		$177K Hold
23,593
– – 0.02% 528
2024
Q3 		$179K Hold
23,593
– – 0.02% 526
2024
Q2 		$146K Buy
23,593
+368
+2% +$2.03K 0.02% 529
2024
Q1 		$118K Hold
23,225
– – 0.01% 543
2023
Q4 		$139K Hold
23,225
– – 0.02% 541
2023
Q3 		$164K Buy
+23,225
New +$167K 0.02% 518

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Legato Capital Management's BCRX Position: Q2 2026 in Review

Legato Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 87,010 shares — an estimated $828K sold.

Legato Capital Management first reported a position in BCRX in Q3 2023 and held it in 11 quarters. The position peaked at $828K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Legato Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 87,010 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $828K.
  • Legato Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Legato Capital Management's BioCryst Pharmaceuticals position peaked at $828K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.